Earnings ·
Vistagen Therapeutics reported fiscal year 2027 first quarter results ending June 30, 2026
VTGNVistagen Therapeutics, Inc.
Vistagen Therapeutics reported fiscal year 2027 first quarter results ending June 30, 2026. The company recognized $1.48 million in revenue due to the expiration of an exclusivity period under its agreement with Fuji Pharma. Operating expenses totaled $14.8 million, comprising $10.9 million in research and development costs and $3.9 million in general and administrative expenses, resulting in a net loss of $13.0 million compared to $15.1 million in the prior year period. Cash, cash equivalents, and marketable securities stood at $31.7 million as of June 30, 2026. Clinically, Vistagen announced preliminary data from the open-label extension of PALISADE-3 for fasedienol and post-hoc data from Phase 3 study PALISADE-4 showing nominally statistically significant improvement in a subpopulation with very severe social anxiety disorder. The company plans to engage with the FDA regarding the future Phase 3 path for fasedienol and received an FDA 'Study May Proceed' letter for refisolone. Additionally, Vistagen appointed Angel S. Angelov as Chief Medical Officer and Douglas J. Williamson to its Board of Directors. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company developing rapid-onset intranasal product candidates called pherines.